Protective association of aspirin/NSAIDs and esophageal cancer: A systematic review and meta-analysis

Gastroenterology - Tập 124 Số 1 - Trang 47-56 - 2003
Douglas A. Corley1,2, Karla Kerlikowske3,4, Rajiv Verma1, Patricia A. Buffler5
1Division of Gastroenterology, Department of Medicine, University of California, San Francisco, California
2Northern California Kaiser Division of Research
3Department of Epidemiology and Biostatistics, University of California, San Francisco, California
4General Internal Medicine Section, Department of Veterans Affairs Medical Center, San Francisco, California
5School of Public Health, University of California, Berkeley, California

Tóm tắt

Từ khóa


Tài liệu tham khảo

McKinney, 1995, Oesophageal and gastric cancer in Scotland 1960-90, Br J Cancer, 71, 411, 10.1038/bjc.1995.84

Hansson, 1993, Increasing incidence of both major histological types of esophageal carcinomas among men in Sweden, Int J Cancer, 54, 402, 10.1002/ijc.2910540309

Hansson, 1993, Increasing incidence of carcinoma of the gastric cardia in Sweden from 1970 to 1985, Br J Surg, 80, 374, 10.1002/bjs.1800800338

Devesa, 1998, Changing patterns in the incidence of esophageal and gastric carcinoma in the United States, Cancer, 83, 2049, 10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.0.CO;2-2

Hansen, 1997, Esophageal and gastric carcinoma in Norway 1958-1992: incidence time trend variability according to morphological subtypes and organ subsites, Int J Cancer, 71, 340, 10.1002/(SICI)1097-0215(19970502)71:3<340::AID-IJC5>3.0.CO;2-Y

Lord, 1998, Rising incidence of oesophageal adenocarcinoma in men in Australia, J Gastroenterol Hepatol, 13, 356, 10.1111/j.1440-1746.1998.tb00646.x

Thomas, 1996, Incidence trends in oesophageal and proximal gastric carcinoma in Victoria, Aust N Z J Surg, 66, 271, 10.1111/j.1445-2197.1996.tb01183.x

Levi, 1991, Adenocarcinoma of the esophagus in Switzerland [letter; comment], JAMA, 265, 2960, 10.1001/jama.265.22.2960b

Yang, 1988, Incidence of cancer of the esophagus in the US by histologic type, Cancer, 61, 612, 10.1002/1097-0142(19880201)61:3<612::AID-CNCR2820610332>3.0.CO;2-Q

Pera, 1993, Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction, Gastroenterology, 104, 510, 10.1016/0016-5085(93)90420-H

Powell, 1990, Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites, Br J Cancer, 62, 440, 10.1038/bjc.1990.314

Blot, 1991, Rising incidence of adenocarcinoma of the esophagus and gastric cardia [see comments], JAMA, 265, 1287, 10.1001/jama.1991.03460100089030

Blot, 1993, Continuing climb in rates of esophageal adenocarcinoma: an update [letter], JAMA, 270, 1320, 10.1001/jama.1993.03510110056031

Daly, 1996, National Cancer Data Base report on esophageal carcinoma, Cancer, 78, 1820, 10.1002/(SICI)1097-0142(19961015)78:8<1820::AID-CNCR25>3.0.CO;2-Z

Sampliner, 1998, Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology, Am J Gastroenterol, 93, 1028, 10.1111/j.1572-0241.1998.00362.x

Heath, 1994, Nonsteroidal anti-inflammatory drugs and human cancer. Report of an interdisciplinary research workshop, Cancer, 74, 2885, 10.1002/1097-0142(19941115)74:10<2885::AID-CNCR2820741023>3.0.CO;2-P

Vainio, 1997, NSAIDs, Barrett's oesophagus and adenocarcinoma prevention [letter], Eur J Cancer Prev, 6, 200

Giovannucci, 1994, Aspirin use and the risk for colorectal cancer and adenoma in male health professionals, Ann Intern Med, 121, 241, 10.7326/0003-4819-121-4-199408150-00001

IARC, 1997, Non-steroidal anti-inflammatory drugs, 1

Thun, 2002, Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues, J Natl Cancer Inst, 94, 252, 10.1093/jnci/94.4.252

Shaheen, 2002, Chemoprevention of gastrointestinal malignancies with nonsteroidal anti-inflammatory drugs, Cancer, 94, 950, 10.1002/cncr.10333

Gupta, 2001, Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2, Nat Rev Cancer, 1, 11, 10.1038/35094017

Ratnasinghe, 1999, Expression of cyclooxygenase-2 in human squamous cell carcinoma of the esophagus; an immunohistochemical survey, Anticancer Res, 19, 171

Morris, 2001, Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia- adenocarcinoma sequence, Am J Gastroenterol, 96, 990

Shureiqi, 2001, Nonsteroidal anti-inflammatory drugs induce apoptosis in esophageal cancer cells by restoring 15-lipoxygenase-1 expression, Cancer Res, 61, 4879

el Attar, 1987, Prostaglandin synthesis by squamous carcinoma cells of head and neck, and its inhibition by non-steroidal anti-inflammatory drugs, J Oral Pathol, 16, 483, 10.1111/j.1600-0714.1987.tb00677.x

Fosslien, 2000, Molecular pathology of cyclooxygenase-2 in neoplasia, Ann Clin Lab Sci, 30, 3

Gallo, 2002, Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma, Hum Pathol, 33, 708, 10.1053/hupa.2002.125376

Kawabe, 2002, Expression of cyclooxygenase-2 is associated with carcinogenesis of the lower part of thoracic esophageal squamous cell carcinoma and p53 expression, Oncology, 62, 46, 10.1159/000048246

Shirvani, 2000, Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure, Gastroenterology, 118, 487, 10.1016/S0016-5085(00)70254-X

Kandil, 2001, Cyclooxygenase-2 expression in Barrett's esophagus, Dig Dis Sci, 46, 785, 10.1023/A:1010700400960

Morgan, 1994, Inflammatory mediators in the oesophagus, Gut, 35, 297, 10.1136/gut.35.3.297

Chang-Claude, 1990, An epidemiological study of precursor lesions of esophageal cancer among young persons in a high-risk population in Huixian, China, Cancer Res, 50, 2268

Stroup, 2000, Meta-analysis of observational studies in epidemiology: a proposal for reporting, JAMA, 283, 2008, 10.1001/jama.283.15.2008

The Cochrane Controlled Trials Register. The Cochrane Library. Volume 4. Oxford: Update Software, updated quarterly, 2001.

Greenland, 1994, Invited commentary: a critical look at some popular meta-analytic methods, Am J Epidemiol, 140, 290, 10.1093/oxfordjournals.aje.a117248

Poole, 1999, Random-effects meta-analyses are not always conservative, Am J Epidemiol, 150, 469, 10.1093/oxfordjournals.aje.a010035

Petitti, 2000

DerSimonian, 1986, Meta-analysis in clinical trials, Controlled Clin Trials, 7, 177, 10.1016/0197-2456(86)90046-2

Chow, 1998, Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia, J Natl Cancer Inst, 90, 150, 10.1093/jnci/90.2.150

Juni, 1999, The hazards of scoring the quality of clinical trials for meta-analysis, JAMA, 282, 1054, 10.1001/jama.282.11.1054

Juni, 2001, Systematic reviews in health care: assessing the quality of controlled clinical trials, BMJ, 323, 42, 10.1136/bmj.323.7303.42

Chalmers, 1983, Bias in treatment assignment in controlled clinical trials, N Engl J Med, 309, 1358, 10.1056/NEJM198312013092204

Jadad, 1996, Assessing the quality of reports of randomized clinical trials: is blinding necessary?, Controlled Clin Trials, 17, 1, 10.1016/0197-2456(95)00134-4

Schulz, 1995, Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials, JAMA, 273, 408, 10.1001/jama.1995.03520290060030

Schulz, 1994, Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals [see comments], JAMA, 272, 125, 10.1001/jama.1994.03520020051014

Imperiale, 1997, Somatostatin or octreotide compared with H2 antagonists and placebo in the management of acute nonvariceal upper gastrointestinal hemorrhage: a meta-analysis, Ann Intern Med, 127, 1062, 10.7326/0003-4819-127-12-199712150-00002

Gerbarg, 1988, Resolving conflicting clinical trials: guidelines for meta-analysis, J Clin Epidemiol, 41, 503, 10.1016/0895-4356(88)90053-4

Imperiale, 1999, Meta-analysis: when and how, Hepatology, 29, 26S

Kleinbaum, 1982

Kendall, 1990

Garidou, 1996, Life-style factors and medical conditions in relation to esophageal cancer by histologic type in a low-risk population, Int J Cancer, 68, 295, 10.1002/(SICI)1097-0215(19961104)68:3<295::AID-IJC5>3.0.CO;2-X

Thun, 1993, Aspirin use and risk of fatal cancer, Cancer Res, 53, 1322

Suleiman, 2000, H2-receptor antagonists may increase the risk of cardio-oesophageal adenocarcinoma: a case-control study, Eur J Cancer Prev, 9, 185, 10.1097/00008469-200006000-00006

Peleg, 1995, Nonsteroidal anti-inflammatory drugs (NSAID's) use and the risk of subsequent cancer of the upper gastrointestinal tract (UGI) [abstract], J Investig Med, 43, 251A

Langman, 2000, Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database, BMJ, 320, 1642, 10.1136/bmj.320.7250.1642

Funkhouser, 1995, Aspirin and reduced risk of esophageal carcinoma, Cancer, 76, 1116, 10.1002/1097-0142(19951001)76:7<1116::AID-CNCR2820760703>3.0.CO;2-I

Coogan, 2000, Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel, Cancer Epidemiol Biomarkers Prev, 9, 119

Farrow, 1998, Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer, Cancer Epidemiol Biomarkers Prev, 7, 97

Cheng, 2000, A case-control study of oesophageal adenocarcinoma in women: a preventable disease, Br J Cancer, 83, 127, 10.1054/bjoc.2000.1121

Sharp, 2001, Risk factors for squamous cell carcinoma of the oesophagus in women: a case-control study, Br J Cancer, 85, 1667, 10.1054/bjoc.2001.2147

Sajadieh, 1999, Nonsteroidal anti-inflammatory drugs after acute myocardial infarction, Am J Cardiol, 83, 1263, 10.1016/S0002-9149(99)00068-5

Konstam, 2001, Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib, Circulation, 104, 2280, 10.1161/hc4401.100078

Jick, 2000, The risk of gastrointestinal bleed, myocardial infarction, and newly diagnosed hypertension in users of meloxicam, diclofenac, naproxen, and piroxicam, Pharmacotherapy, 20, 741, 10.1592/phco.20.9.741.35209

Garcia Rodriguez, 2000, Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women, Epidemiology, 11, 382, 10.1097/00001648-200007000-00004

Thun, 1991, Aspirin use and reduced risk of fatal colon cancer, N Engl J Med, 325, 1593, 10.1056/NEJM199112053252301

Pasricha, 1995, The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis, Gastroenterology, 109, 994, 10.1016/0016-5085(95)90411-5

Nugent, 1993, Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis, Br J Surg, 80, 1618, 10.1002/bjs.1800801244

Labayle, 1991, Sulindac causes regression of rectal polyps in familial adenomatous polyposis, Gastroenterology, 101, 635, 10.1016/0016-5085(91)90519-Q

Rubio, 1989, Effect of indomethacin in autotransplanted colonic tumors, Dis Colon Rectum, 32, 488, 10.1007/BF02554503

Rubio, 1986, Further studies on the therapeutic effect of indomethacin on esophageal tumors, Cancer, 58, 1029, 10.1002/1097-0142(19860901)58:5<1029::AID-CNCR2820580508>3.0.CO;2-D

Rubio, 1984, Antitumoral activity of indomethacin on experimental esophageal tumors, J Natl Cancer Inst, 72, 705

Tsibouris, 2001, NSAIDs do not protect patients with Barrett oesophagus from adenocarcinoma development (abstr), Gastroenterology, 120, A595, 10.1016/S0016-5085(08)82959-9

Schnell, 1997, Does aspirin (ASA) or NSAID use influence the development of esophageal adenocarcinoma (ADCA)?, Gastroenterology, 112, A652

Sample, 2002, Post-study aspirin intake and factors motivating participation in a colorectal cancer chemoprevention trial, Cancer Epidemiol Biomarkers Prev, 11, 281

Patterson, 1998, Cancer-related behavior of vitamin supplement users, Cancer Epidemiol Biomarkers Prev, 7, 79

Catella-Lawson, 2001, Cyclooxygenase inhibitors and the antiplatelet effects of aspirin, N Engl J Med, 345, 1809, 10.1056/NEJMoa003199

Blot, 1994, Esophageal cancer trends and risk factors, Semin Oncol, 21, 403

Blot, 1999, The changing epidemiology of esophageal cancer, Semin Oncol, 26, 2

Brown, 1994, Adenocarcinoma of the esophagus and esophagogastric junction in white men in the United States: alcohol, tobacco, and socioeconomic factors, Cancer Causes Control, 5, 333, 10.1007/BF01804984

Gammon, 1997, Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia [see comments], J Natl Cancer Inst, 89, 1277, 10.1093/jnci/89.17.1277

Lagergren, 1999, Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma, N Engl J Med, 340, 825, 10.1056/NEJM199903183401101

Shaheen, 2000, Is there publication bias in the reporting of cancer risk in Barrett's esophagus? [see comments], Gastroenterology, 119, 333, 10.1053/gast.2000.9302

Taylor, 1994, Prevention of esophageal cancer: the nutrition intervention trials in Linxian, China, Cancer Res, 54, 2029s